See more : GE Power India Limited (GEPIL.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Enochian Biosciences, Inc. (ENOB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enochian Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- KG Intelligence CO., LTD. (2408.T) Income Statement Analysis – Financial Results
- PAVmed Inc. (PAVMW) Income Statement Analysis – Financial Results
- Crescent Capital BDC, Inc. (CCAP) Income Statement Analysis – Financial Results
- Better For You Wellness, Inc. (BFYW) Income Statement Analysis – Financial Results
- Sachem Capital Corp. (SACH) Income Statement Analysis – Financial Results
Enochian Biosciences, Inc. (ENOB)
About Enochian Biosciences, Inc.
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 42.77K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 121.86K | 113.50K | 123.59K | 391.42K | 366.27K | 71.71K | 18.48K | 14.53K | 32.67K | 314.64K | 0.00 | 0.00 |
| Gross Profit | -121.86K | -113.50K | -123.59K | -391.42K | -366.27K | -71.71K | -18.48K | -14.53K | 10.10K | -314.64K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 23.62% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.71M | 4.17M | 8.37M | 15.72M | 4.69M | 2.50M | 616.96K | 62.76K | 804.19K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 24.17M | 15.32M | 14.33M | 7.56M | 7.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 383.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.56M | 15.32M | 14.33M | 7.56M | 7.12M | 8.42M | 2.60M | 2.32M | 1.33M | 2.11M | 37.09K | 29.95K |
| Other Expenses | 54.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 81.64M | 19.60M | 22.83M | 23.40M | 11.92M | 10.92M | 3.22M | 2.39M | 2.13M | 2.11M | 37.09K | 29.95K |
| Cost & Expenses | 81.64M | 19.60M | 22.83M | 23.40M | 11.92M | 10.99M | 3.24M | 2.40M | 2.16M | 2.43M | 37.09K | 29.95K |
| Interest Income | 0.00 | 0.00 | 122.04K | 13.18K | 50.30K | 73.49K | 45.82K | 0.00 | 0.00 | 5.94K | 0.00 | 0.00 |
| Interest Expense | 1.01M | 706.96K | 372.84K | 379.61K | 104.28K | 43.00 | 143.26K | 26.26K | 2.36K | 84.55K | 497.00 | 0.00 |
| Depreciation & Amortization | 121.86K | 113.50K | 123.59K | 123.53K | 366.27K | 71.71K | 18.48K | 14.53K | 27.40K | 45.20K | 0.00 | 0.00 |
| EBITDA | -79.52M | -19.48M | -22.70M | -23.28M | -11.51M | -17.94M | -5.31M | -2.39M | -2.17M | -2.42M | -37.09K | -29.95K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,894.99% | 0.00% | 0.00% | 0.00% |
| Operating Income | -81.64M | -38.56M | -116.08M | -23.40M | -11.92M | -10.99M | -3.24M | -2.40M | -2.12M | -2.43M | -37.09K | -29.95K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,959.04% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 989.12K | -1.13M | 2.65M | -3.45M | 507.41K | -7.03M | -3.19M | 192.72K | -77.10K | -119.20K | -497.00 | 0.00 |
| Income Before Tax | -80.65M | -39.68M | -113.43M | -26.85M | -11.42M | -18.02M | -6.42M | -2.21M | -2.20M | -2.55M | -37.59K | -29.95K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,139.30% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 706.96K | 34.00 | -125.28K | 104.28K | 1.00 | -111.72K | -64.88K | -462.79K | -177.54K | 0.00 | 0.00 |
| Net Income | -80.65M | -39.68M | -113.43M | -26.72M | -11.42M | -18.02M | -6.31M | -2.14M | -1.74M | -2.37M | -37.59K | -29.95K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,057.24% | 0.00% | 0.00% | 0.00% |
| EPS | -0.84 | -0.71 | -2.16 | -0.57 | -0.25 | -0.48 | -0.29 | -0.17 | -0.18 | -0.32 | -0.01 | 0.00 |
| EPS Diluted | -0.84 | -0.71 | -2.16 | -0.57 | -0.25 | -0.48 | -0.29 | -0.17 | -0.18 | -0.32 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 96.25M | 56.27M | 52.53M | 47.17M | 46.33M | 37.55M | 21.94M | 12.27M | 9.53M | 7.50M | 5.00M | 10.44M |
| Weighted Avg Shares Out (Dil) | 96.25M | 56.27M | 52.53M | 47.17M | 46.33M | 37.55M | 21.94M | 12.27M | 9.53M | 7.50M | 5.00M | 10.44M |
Pioneering Research Institute In Los Angeles Moves One Step Closer To Finding A Cure For HIV
ENOB Stock Price Increased 53.97%: Why It Happened
Here's Why Enochian BioSciences Stock Skyrocketed Today
Enochian BioSciences Announces $29 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
ENOB Stock: The HIV Treatment News That Has Enochain Biosciences Skyrocketing Today
ENOB Stock Price: Over 140% Increase Pre-Market Details
Hot Penny Stocks For Your Weekly Watchlist in June
Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential HIV Cure
Enochian BioSciences announces Scientific Presentation of a Person with HIV Exhibiting Controlled Blood Levels of Virus for 255 Days Following Treatment with a Novel Cellular Therapy
A Promising Approach To HIV Cell Therapy, With Exciting Preliminary Results, Was Presented Recently At The Leading Conference On Gene And Cell Therapy
Source: https://incomestatements.info
Category: Stock Reports